| TOP STORY | Jekyll and Hyde: Cells’ Executioner Can Also Stave Off Death An enzyme viewed as an executioner, because it can push cells to commit suicide, may actually short circuit a second form of cell death, researchers have discovered. [Press release from Emory University Woodruff Health Sciences Center discussing online prepublication in Nature] |
| SPECIAL FEATURE | Cell Therapy News is now on Facebook. Join us! Follow us on Twitter! @Immune_News Interested in recruiting talented individuals? Post your career opportunities in Immune Regulation News at no cost. Contact us at info@connexoncreative.com |
| INDUSTRY NEWS | Bayhill Therapeutics Announces the Successful Clearance of an IND for BHT-3034 for the Treatment of Myasthenia Gravis Bayhill Therapeutics Inc, a clinical-stage biopharmaceutical company utilizing its proprietary BHT-DNA™ platform to develop novel and targeted autoimmune and immune-mediated disease treatments, announced the successful clearance of an IND with the US FDA for BHT-3034, a disease-modifying DNA plasmid vaccine immunotherapy for patients with the autoimmune neuromuscular junction disease myasthenia gravis. [FierceBiotech] Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections Sangamo BioSciences, Inc. announced the presentation of positive preliminary clinical data from its Phase I trial (SB-728-902). [Sangamo BioSciences, Inc. Press Release] China Follows B.C.’s Lead on HIV/AIDS Treatment The Chinese government has announced it will use a treatment strategy developed in B.C. to combat the spread of HIV and AIDS in China. [The Vancouver Sun] Phase I/II Clinical Study of IFN(alpha)-Kinoid for Lupus Fully Enrolled Neovacs, a biotech company focused on an active immunotherapy technology platform (Kinoids™) with applications in the treatment of autoimmune diseases, inflammatory diseases and cancer, announced that its IFN-K-001 clinical study has recruited all 28 patients called for by the study protocol and consistent with the Company’s development plan. [Neovacs Press Release] Lycera Announces Research Collaboration with Merck to Discover, Develop and Commercialize Drugs for Autoimmune Diseases Lycera Corporation announced that it has entered into an exclusive research collaboration with Merck to discover, develop and commercialize small molecules that target T-helper 17 cells, key mediators of inflammation. [Lycera Corporation Press Release] |
|
|
|